top
Search terms
Results 1 - 5 of 5 - ordered by :
Ehjcvp

Abstract Aims Therapeutic windows for residual platelet reactivity in patients with coronary artery disease on P2Y12 inhibitors were proposed in a consensus document. Conclusions Our results suggest ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Minka J.A. Vries, Heleen J. Bouman, Renske H. Olie, Leo F. Veenstra, Suzanne Zwaveling, Paul W.M. Verhezen, Arina J. ten ...

Date : 07/09/2016
Ehjcvp

Introduction Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have been used in clinical practice for more than a century and are among the most widely used drugs worldwide for the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, ...

Date : 01/04/2016 Item size : 461588 bytes
Ehjcvp

Glycoprotein IIb/IIIa receptor inhibitors (GPIs) block the final common pathway leading to platelet aggregation that occurs via the cross-linking of fibrinogen and von Willebrand factor upon exposure ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Jeffrey D. Wessler, Robert P. Giugliano

Date : 01/04/2015
Ehjcvp

[...]anti-GPIIb/IIIa agents are used in conditions such as acute coronary syndrome undergoing percutaneous intervention where the thrombotic tendency of human body become extremely high.1,2 Since the ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Shinichi Goto, Shinya Goto

Date : 01/01/2015 Item size : 149314 bytes
Ehjcvp

Writing and submitting a manuscript forces researchers to put their data together, analyse them appropriately, make sense of them, and discuss their implications for science and ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Thomas F. Lüscher

Date : 01/01/2015